Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
acquisition tags : Biotech-bay save search
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
Published: 2024-02-12 (Crawled : 14:30) - biospace.com/
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.35%
H: 2.36%
C: 1.42%
CBAY | $32.48 0.03% 8.4M
|
Health Technology
|
| O: 27.92%
H: 0.97%
C: 0.88%
liver acquisition sciences therapeutics
Quince Therapeutics Completes Acquisition of EryDel S.p.A.
Published: 2023-10-23 (Crawled : 12:00) - biospace.com/
QNCX | $1.055 5.5% 5.21% 81K
|
Professional, Scientific, and T...
|
| O: -1.75%
H: 5.99%
C: 2.9%
acquisition therapeutics
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics
Published: 2023-09-05 (Crawled : 14:00) - biospace.com/
TVTX | $5.805 -3.09% -3.19% 970K
|
Health Technology
|
| O: -1.08%
H: 2.24%
C: -3.54%
MIRM | $23.6 -1.05% -1.06% 400K
|
Health Technology
|
| O: 0.42%
H: 7.76%
C: 4.46%
rare liver treatment acquisition pharmaceuticals therapeutics
Jasper Therapeutics Appoints Daniel Adelman, M.D., as Acting Chief Medical Officer
Published: 2023-03-23 (Crawled : 14:00) - biospace.com/
JSPR | $23.28 -2.27% -2.32% 120K
|
|
| O: -0.52%
H: 4.19%
C: 1.57%
medical therapeutics
HeartBeam Announces Acquisition of LIVMOR Assets
Published: 2023-03-14 (Crawled : 19:00) - biospace.com/
BEAT | $2.09 -3.24% -3.35% 42K
|
Health Technology
|
| O: 1.27%
H: 7.21%
C: -3.13%
acquisition
Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition
Published: 2023-02-02 (Crawled : 14:20) - biospace.com/
VTGN | $4.69 0.43% 0.43% 200K
|
Health Technology
|
| O: 3.55%
H: 14.92%
C: 5.18%
acquisition pharmaceuticals
Jasper Therapeutics Announces Development Prioritization of Briquilimab in Chronic Diseases, Including Urticaria and Lower-Risk MDS, and Stem Cell Transplant for Sickle Cell Disease and Other Rare Diseases
Published: 2023-01-10 (Crawled : 15:20) - biospace.com/
JSPR | $23.28 -2.27% -2.32% 120K
|
|
| O: 23.27%
H: 9.18%
C: -15.82%
rare disease urticaria therapeutics
Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research
Published: 2023-01-04 (Crawled : 15:00) - biospace.com/
A | $132.44 -1.57% -0.36% 1.9M
|
Health Technology
|
| O: 1.07%
H: 0.92%
C: 0.01%
acquisition research cancer
OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights
Published: 2022-11-15 (Crawled : 13:00) - biospace.com/
LGND | News | $72.61 -7.94% -8.62% 130K
|
Health Technology
|
| O: 1.8%
H: 2.3%
C: -2.72%
IMVT 4 | $28.34 -0.32% -0.32% 1.2M
|
Health Technology
|
| O: 2.22%
H: 3.33%
C: 3.02%
financial results
Bruker Announces Acquisition of Inscopix for Neuroscience Research
Published: 2022-11-08 (Crawled : 12:20) - biospace.com/
BRKR | News | $78.56 -5.28% -5.58% 2.2M
|
Health Technology
|
| O: 0.33%
H: 1.82%
C: -0.14%
acquisition research
Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Published: 2022-08-24 (Crawled : 22:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -4.66%
H: 0.0%
C: -1.69%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.48%
H: 0.0%
C: 0.0%
LGND | News | $72.61 -7.94% -8.62% 130K
|
Health Technology
|
| O: -0.75%
H: 3.45%
C: 2.49%
tecvayli treatment approval
Innoviva Completes Acquisition of La Jolla Pharmaceutical
Published: 2022-08-22 (Crawled : 13:00) - biospace.com/
INVA | $14.69 1.45% 1.43% 640K
|
Health Technology
|
| O: -0.92%
H: 0.57%
C: -0.71%
acquisition
Innoviva Completes Acquisition of Entasis Therapeutics
Published: 2022-07-11 (Crawled : 14:20) - biospace.com/
INVA | $14.69 1.45% 1.43% 640K
|
Health Technology
|
| O: 1.16%
H: 0.0%
C: 0.0%
acquisition therapeutics
Blade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference
Published: 2022-05-16 (Crawled : 15:00) - biospace.com/
BIOT | $10.15 -0.78% -0.2% 44K
|
|
| O: 0.1%
H: 0.05%
C: 0.0%
conference preclinical cudetaxestat therapeutics international pre-clinical phase 1
Jasper Therapeutics to Host In-Person Key Opinion Leader Webinar on Transforming Hematopoietic Stem Cell Therapies
Published: 2022-04-22 (Crawled : 14:00) - biospace.com/
JSPR | $23.28 -2.27% -2.32% 120K
|
|
| O: 0.39%
H: 4.67%
C: -1.56%
therapeutics therapy
Jasper Therapeutics to Present Updated Data on JSP191 Conditioning in SCID Patients at the 2022 Clinical Immunology Society Annual Meeting
Published: 2022-03-31 (Crawled : 16:00) - biospace.com/
JSPR | $23.28 -2.27% -2.32% 120K
|
|
| O: 2.69%
H: 7.27%
C: 3.2%
jsp191 immunology therapeutics
Arcellx Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results
Published: 2022-03-24 (Crawled : 23:00) - biospace.com/
ACLX | $54.5 1.77% 1.74% 600K
|
|
| O: -1.04%
H: 5.27%
C: 3.95%
IQMD | $11.04 0.09% 220K
|
n/a
|
| O: -0.3%
H: 0.3%
C: 0.3%
results
Blade Therapeutics to Present Data from Preclinical and Phase 1 Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference
Published: 2022-03-24 (Crawled : 12:30) - biospace.com/
BIOT | $10.15 -0.78% -0.2% 44K
|
|
| O: -0.1%
H: 0.0%
C: 0.0%
conference therapeutics preclinical international cudetaxestat phase 1 pre-clinical
Jasper Therapeutics Announces JSP191 Phase 1b MDS/AML Late Breaking Data Presentation at the 2022 Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR
Published: 2022-02-24 (Crawled : 00:00) - biospace.com/
JSPR | $23.28 -2.27% -2.32% 120K
|
|
| O: 1.44%
H: 0.0%
C: 0.0%
jsp191 phase 1b therapeutics presentation cel phase 1 therapy aml phase 2b
IDEAYA Biosciences Announces Acquisition of Proprietary INQUIRE™ Chemical Library to Enhance Synthetic Lethality Drug Discovery Platform
Published: 2022-01-05 (Crawled : 12:00) - biospace.com/
IDYA | $37.63 -6.32% -6.75% 820K
|
Health Technology
|
| O: -7.58%
H: 0.0%
C: 0.0%
acquisition drug bioscience drug discovery platform
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.